<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343342</url>
  </required_header>
  <id_info>
    <org_study_id>FAS</org_study_id>
    <nct_id>NCT01343342</nct_id>
  </id_info>
  <brief_title>Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors</brief_title>
  <acronym>FAS</acronym>
  <official_title>Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine whether n-3 PUFA-induced changes in metabolic
      risk factors are influenced by genetic variations within genes acting as fatty acids sensors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to examine whether n-3 PUFA-induced changes in metabolic
      risk factors are influenced by genetic variations within genes acting as fatty acids sensors.
      To do so, the metabolic risk factor response to an n-e PUFA supplementation will be compared
      in carriers and non-carriers of polymorphism within genes acting as fatty acids sensors.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood lipids (Total cholesterol, HDL-Cholesterol, Triglycerides)</measure>
    <time_frame>Before and after a 6-weeks supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Before and after a 6-weeks supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometric measures (waist and hip girth)</measure>
    <time_frame>Before and after a 6-weeks supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glycemia and insulin levels</measure>
    <time_frame>Before and after a 6-weeks supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression levels</measure>
    <time_frame>Before and after a 6-weeks supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>capsules omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega-3 supplementation (3g EPA+DHA/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>n-3 PUFA supplementation</intervention_name>
    <description>3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)</description>
    <arm_group_label>capsules omega-3</arm_group_label>
    <other_name>MEG-3 from Ocean Nutrition Canada,Nova Scotia,Canada.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men and women aged between 18 to 50 years;

          -  having a BMI between 25 and 40kg/m2;

          -  plasma triglycerides levels &lt;4.0 mmol/L;

          -  non-smokers;

          -  free of any thyroid or metabolic disorders requiring treatment such as diabetes,
             hypertension, severe dyslipidemia, and coronary heart disease.

        Exclusion Criteria:

          -  subjects taking medication for hyperlipidemia, hypertension, diabetes or taking
             anticoagulant or n-3 PUFA supplementation;

          -  having a taste aversion for fish, fish allergy or regular alcohol drinker;

          -  body mass index &gt; 40kg/m2;

          -  pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Vohl, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Nutraceutical and Functional Foods (INAF), Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nutraceutical and Functional Foods (INAF), Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1V0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Marie-Claude Vohl</investigator_full_name>
    <investigator_title>Professeur</investigator_title>
  </responsible_party>
  <keyword>omega-3</keyword>
  <keyword>PUFA</keyword>
  <keyword>fatty acids</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

